Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/04/23
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/23
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual MeetingBusiness Wire • 11/05/22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with ThalassemiaBusiness Wire • 09/29/22
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines ConferenceBusiness Wire • 09/27/22
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia VeraBusiness Wire • 09/08/22
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment ConferenceBusiness Wire • 05/18/22
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma CollaborationBusiness Wire • 04/25/22
Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/06/22
Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)Business Wire • 04/03/22
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual MeetingBusiness Wire • 04/03/22
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501Business Wire • 03/23/22
Silence Therapeutics plc (SLN) CEO Craig Toooman on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022Business Wire • 03/02/22
Silence Therapeutics Appoints Craig Tooman President and Chief Executive OfficerBusiness Wire • 02/21/22